-
DataDirect Networks to Speak at XGen Congress, the Premier Conference for Next-Generation Genomic Technologies
Storage Experts to Discuss Challenges and Solutions for High-Throughput Sequencing and Next-Generation Cloud Storage Initiatives
-
CambridgeSoft's E-Notebook Selected by VIB, a Life Sciences Research Institute From Flanders, Belgium
CAMBRIDGE, UK--(Marketwire - March 10, 2010) - CambridgeSoft today announces that VIB, a Belgium based non-profit life sciences research institute, has selected CambridgeSoft's E-Notebook for deployment to over 400 VIB researchers. This decision follows a successful pilot study carried out in 2009. E-Notebook, an application which facilitates research collaboration and knowledge management, will be rolled out during 2010 to VIB scientists active in many biotechnology research domains (genomics, plant biology, neurobiology, microbiology, etc) at four different universities in Flanders.
-
MichBio Announces Annual Business Meeting Keynote and Pre-Meeting Workshop
ANN ARBOR, MI--(Marketwire - March 10, 2010) - MichBio, the association for Michigan biosciences, will for the first time host its Annual Business Meeting and Showcase in Grand Rapids. The event will be held at Grand Valley State University's Eberhard Center on April 21 and feature a strolling dinner amid bioscience-related company exhibits from 5-7 p.m., followed by a keynote address by Mark B. Leahey, president and CEO of the Medical Device Manufacturers Association. The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, DC, that represents research-driven medical technology companies.
-
Critical Outcome Technologies Inc. Reports Fiscal 2010 Third Quarter Financial Results
LONDON, ONTARIO--(Marketwire - March 10, 2010) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced fiscal 2010 third quarter financial results today for the three and nine month periods ended January 31, 2010.
"We made significant headway in the development and commercialization appeal of COTI-2 during the quarter as we announced an agreement with TGen Drug Development (TD2) for the management of our investigational new drug (IND) animal testing and filing of our IND submission to the Food and Drug Administration in the United States," said Mr. Michael Cloutier, Chief Executive Officer of COTI. "We will be continuing our efforts to obtain the necessary financing to move forward with this testing during the fourth quarter and realize on this important milestone for commercial success."
-
Drug Manufacturing Companies Are Committed to Various R&D to Supply the Rise in Demand for Chronic Health Conditions
-
Proteonomix, Inc. Announces the Formation of PRTMI RD S.R.L. as a PRTMI Subsidiary
MOUNTAINSIDE, NJ--(Marketwire - March 10, 2010) - Proteonomix, Inc. (PINKSHEETS: PROT) announces that its wholly-owned subsidiary, Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI"), has created a subsidiary, PRTMI RD S.R.L., a corporation organized under the laws of the Dominican Republic ("DR").
-
Evogene Reports Fourth Quarter and Annual 2009 Financial Results
REHOVOT, ISRAEL--(Marketwire - March 10, 2010) - Evogene Ltd. (TASE: EVGN) announced today
its financial results for the fourth quarter and year ended December 31,
2009.
-
Eurand to Present at Barclays Capital Global Healthcare Conference
PHILADELPHIA, PA--(Marketwire - March 10, 2010) - Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Barclays Capital 2010 Global Healthcare Conference. Gearóid Faherty, Eurand's Chairman and Chief Executive Officer, will be presenting.
-
AspenBio Pharma Enters Into Development and Supply Agreement for AppyScore(TM) Cassette With BBInternational
Agreement Aligns AspenBio With a Leading OEM Provider of Lateral Flow Assays and Completes the Supply Chain for Commercial Production of the AppyScore(TM) Test
-
Lorus Therapeutics Announces Allowance of a Patent on its Small Molecule Program
Australian Patent Provides Broad Protection of its Small Molecule Drug Candidates
-
Entest BioMedical Strengthens Its Research Capabilities by Adding Clinical Trials Expert Dr. Vladimir Bogin to Its Scientific Advisory Board
Dr. Bogin Is an Expert in Stem Cell Clinical Trials and the CEO of Cromos Pharma LLC; Company Sees Addition Aiding Clinical Trials Development for COPD Stem Cell Treatment Model
-
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, CA--(Marketwire - March 10, 2010) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its fast skeletal muscle troponin activator,
CK-2017357, has been granted orphan-drug designation by the U.S. Food and
Drug Administration (FDA) for the potential treatment of amyotrophic
lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease.
CK-2017357 is the lead drug candidate that has emerged from the company's
skeletal sarcomere activator program. Cytokinetics plans to initiate a
Phase II Evidence of Effect clinical trial for CK-2017357 in ALS patients
in the first half of 2010.
-
IntelGenx Granted Bupropion Patent
SAINT LAURENT, QUEBEC--(Marketwire - March 10, 2010) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") today announced that the U.S. Patent and Trademark Office ("USPTO") issued patent number 7,674,479 on March 9, 2010 for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of Bupropion hydrochloride ("HCl"), the active ingredient in Wellbutrin XL®.
-
Allon's CEO Presenting at BIO-Europe Spring
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 9, 2010) - Allon Therapeutics Inc. (TSX:NPC) President and CEO Gordon McCauley will present an update of the Company's business progress on Wednesday, March 10 at 11:15 CET at the BIO-Europe Spring 2010 4th Annual International Partnering Conference in Barcelona, Spain.
-
March Is Multiple Sclerosis Awareness Month
CHERRY HILL, NJ--(Marketwire - March 9, 2010) - The Multiple Sclerosis Association of America (MSAA) encourages everyone to take time this March to learn about multiple sclerosis (MS) and discover all of the programs and services MSAA offers to everyone affected by MS.
-
ChemSW Releases New Best Practices White Paper on How to Gain Complete Control of Chemical Inventory
FAIRFIELD, CA--(Marketwire - March 9, 2010) - ChemSW, Inc. today announced the release of a new in-depth white paper that examines best practices for effectively controlling and reporting chemical inventory. Titled "How to Gain Complete Control of Your Chemical Inventory," the white paper provides tips and techniques for ensuring that chemical inventory is managed in a safe, efficient and cost-effective manner.
-
Emerging World Pharma Inc. Provides Initial Investment Into Private West African Generic Pharmaceutical Company
MANASSAS, VA--(Marketwire - March 9, 2010) - Emerging World Pharma Inc. (PINKSHEETS: EWPI), an investor in generic based pharmaceutical companies manufacturing within developing nations, has provided an initial investment into a private generic pharmaceutical company located in West Africa. The investment would entitle Emerging World Pharma a percentage of profits obtained from an exclusive marketing and distribution agreement of generic pharmaceuticals. In addition the company has negotiated an option that would considerably increase the percentage of returns on profit with ongoing investments.
-
Medtech Deals Remain Attractive to VCs and Business-Development Execs at Elsevier Business Intelligence's 'IN3 West'
Nearly 200 Attendees and 40 Innovative Presenting Companies Along With a Dozen Sponsors Convened Last Week in Las Vegas
-
Update: HearUSA to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
WEST PALM BEACH, FL--(Marketwire - March 9, 2010) - HearUSA, Inc. (NYSE Amex: EAR), a
leader among the nation's hearing care providers, has been invited to
present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
to be held at The Ritz Carlton in Dana Point, CA on March 15-17, 2010.
-
Pfizer encourage la population à donner au suivant
Objectif : amasser 50 000 $ pour les athlètes paralympiques du Canada en mars 2010
-
Mila Sales Spike With Lifemax Prosperity Promotion
Largest Promotion in Company's History Yields Bonuses Exceeding 250,000 USD
-
Pfizer Encourages Canada to Pay it Forward
Sets goal to raise $50,000 for Paralympians this March 2010
-
QUMAS Wins Deloitte Best Managed Companies Award
JERSEY CITY, NJ--(Marketwire - March 9, 2010) - QUMAS, the leading provider of Compliance Solutions to highly regulated companies, has won the Deloitte Best Managed Companies Award.
-
Cleveland BioLabs to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
BUFFALO, NY--(Marketwire - March 9, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference, March 15-17, in Laguna Niguel, CA.
-
Top-Tier Medical Device Manufacturer Renews Agreement for Another 5 Years With OmniComm
FORT LAUDERDALE, FL--(Marketwire - March 9, 2010) - OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions, announced today that a leading cardiovascular medical device manufacturer has renewed its contract with the company for another 5 years. The agreement extends and expands the previous five-year agreement which generated over $2.5 Million in revenue for the company over the past three years. The company expects revenue for this customer to increase.
-
Global Pharmaceutical Company Chooses Ingeniux for Multi-Site Web Content Management
Ingeniux Will Power Over 30 Global Websites and Automate Compliance Safeguards
-
Don Cherry, B.C Premier Campbell, the Founding President of the International Paralympic Committee to Join in "COLD-FX's Salute to the 2010 Paralympic Games" on Eve of Opening Ceremonies
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 9, 2010) -
-
iogen to Be Presented at Natural Products Expo West
Scientific Bio-Logics Welcomes iogen
-
HQ Sustainable Maritime Industries, Inc. to Announce Results for the Fourth Quarter Ended December 31, 2009
SEATTLE, WA--(Marketwire - March 9, 2010) - HQ Sustainable Maritime Industries, Inc.
(NYSE Amex: HQS) ("HQS" or the "Company"), a leading producer of
functional, sustainable Tilapia biomass, including fish and personal
healthcare products, will announce results for the fourth quarter ended
December 31, 2009 on Monday, March 15, 2010, after market close. The
Company will also host a conference call to discuss these results with
additional comments and details. Participating on the call will be Norbert
Sporns, President and Chief Executive Officer, and Jean-Pierre Dallaire,
Chief Financial Officer.
-
New Report Outlines Stem Cell R&D Trends
-
MSC.Software Releases Patran 2010
Dramatic Performance and Usability Improvements Provide Access to Broader Range of Real World Behaviors
-
PatientsLikeMe Collaborates With Novartis to Create an Open Online Community for Organ Transplant Recipients
Two New Programs Unveiled to Help Patients "Give Back"
-
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
BOTHELL, WA--(Marketwire - March 9, 2010) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Tuesday, March 16, 2010. Subsequently, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time), Dr. Leslie Hudson, AVI's President and Chief Executive Officer, and J. David Boyle II, AVI's Senior Vice President and Chief Financial Officer, will host a conference call to discuss the fourth quarter and full year 2009 financial results and to provide a corporate update.
-
Universal Detection Technology Receives Purchase Order From the City of Burbank Fire Department for Bioterrorism Detection Equipment
Order Equips First Responders in Hollywood Entertainment Hub With Tools to Protect Community From Bioterrorism Attack
-
Palomar Technologies to Exhibit at IMAPS Device Packaging Conference
Palomar's Emphasis Will Be on Its Model 8000 Wire Bonder/Ball (Stud) Bumper's Versatility, With a Method That Enables Higher Density Packages
-
Imaging3 to Host Conference Call Regarding FDA Progress
BURBANK, CA--(Marketwire - March 8, 2010) - Imaging3T, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Wednesday, March 10, 2010 at 1:00pm PST, (4:00pm EST) the company's CEO, Mr. Dean Janes, will be hosting a conference call. To join the conference call, please call 1-888-732-6202 and enter passcode 745546 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation.
-
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of a Clinical Study Assessing Relative Abuse Potential
PALATINE, IL and BRISTOL, TN--(Marketwire - March 8, 2010) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) today announced top-line results from Study AP-ADF-114 ("Study 114") titled "A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox® (oxycodone HCl and niacin) Tablets in Non-Dependent Recreational Opioid Users." Study 114 top-line results demonstrate that two different potentially abused excess oral doses of Acurox® Tablets are significantly disliked compared to equivalent excess oral doses of oxycodone HCl tablets alone (without niacin). All five co-primary endpoints comparing the like/dislike of excess doses of Acurox® Tablets with the like/dislike of excess doses of oxycodone HCl tablets
-
NewCardio CEO Interviewed on CorporateProfile.com
NEW YORK, NY--(Marketwire - March 8, 2010) - NewCardio, Inc. (OTCBB: NWCI) announced today that CEO, Dr. Branislav Vajdic, was interviewed on CorporateProfile.com.
-
Foundation 4Life Responde al Terremoto de Magnitud 8.8 en Chile
SALT LAKE CITY, UT--(Marketwire - March 8, 2010) - El sábado 27 de febrero, uno de los
terremotos más grandes en la historia azotó el país de Chile. El terremoto
tuvo una magnitud de 8.8 en la escala de Richter y causó un tsunami que
devastó las comunidades de la costa al sur de la capital de Santiago de
Chile.
-
Foundation 4Life Responds to 8.8 Quake in Chile
SALT LAKE CITY, UT--(Marketwire - March 8, 2010) - On Saturday, February 27, one of the largest earthquakes in recent history hit the country of Chile. The quake measured 8.8 on the Richter scale and set off a tsunami that devastated coastal communities south of the capital, Santiago.
-
Product Launch at AAOS 2010 New Orleans
LONDON--(Marketwire - March 8, 2010) -
Smith and Nephew Continues to Deliver its Strategic Priorities
Company to introduce new and innovative products at the American
Academy of Orthopaedic Surgeons 2010 Annual Meeting in New Orleans
Representatives from across the business to attend
London, United Kingdom, March 8, 2010 - Smith & Nephew plc (LSE: SN,
NYSE: SNN), the global medical technology business, continues to
deliver on its strategic priorities by introducing new and innovative
products from its Orthopedics and Endoscopy business units at this
yearOs American Academy of Orthopaedic Surgeons ("AAOS") Annual
Meeting. Smith & Nephew's presence at this year's Annual Meeting will
feature the launch of several new products, as well as advances in
Smith & Nephew's current portfolio, and representatives from Smith &
Nephew Orthopaedic's medical education platform, KLEOS, will be on
hand. The combined success of Smith & Nephew's Orthopae
-
FFF Enterprises Observes National Patient Safety Awareness Week
The Nation's Largest Distributor of Critical-Care Biopharmaceuticals Announces Its Participation in National Patient Safety Awareness Week; the Company Will Launch a Multi-Faceted Campaign Aimed at Empowering Patients to Become Involved in Their Own Healthcare
-
Ambrilia Biopharma dépose son rapport bi-hebdomadaire sur la situation et un changement au sein de son conseil d'administration
MONTRÉAL, QUÉBEC--(Marketwire - 8 mars 2010) -
-
Ambrilia Biopharma Provides Bi-Weekly Update on Its Status and A Change to Its Board of Directors
MONTREAL, QUEBEC--(Marketwire - March 8, 2010) -
-
GENEWIZ Adds Gene Synthesis Service to Molecular Biology Service Portfolio
SOUTH PLAINFIELD, NJ--(Marketwire - March 8, 2010) - GENEWIZ, Inc., a leading provider of DNA
services, announced the expansion of its molecular biology portfolio with
the addition of Gene Synthesis services. Gene synthesis provides
researchers with a time- and cost-saving alternative to molecular cloning,
DNA engineering, protein engineering and directed evolution for custom
construct production.
-
Novo Nordisk A/S - Share repurchase programme
BAGSVAERD, DENMARK--(Marketwire - March 8, 2010) -
-
Autism Walk Expects 15,000 People
Walk Now for Autism Speaks, April 24, Pasadena Rose Bowl
-
OctoPlus publishes prospectus for listing of shares issued on 18 December 2009
LEIDEN, NETHERLANDS--(Marketwire - March 8, 2010) -
-
S3 Investment Company Announces Ongoing Work by Redwood Capital Subsidiary for Additional SFDA Approvals for First Product to Be Distributed in China
DANVILLE, CA--(Marketwire - March 8, 2010) - S3 Investment Company, Inc. (PINKSHEETS: SIVC) today announced that the company's Redwood Medical subsidiary, which distributes Western medical technologies and products into the China market, is currently working on additional State Food and Drug Administration (SFDA) approvals for the first product it has signed to distribute in China.
-
Leading Experts Spotlight "A Day in the Life With Glaucoma" to Demonstrate the Growing Impact of Glaucoma on Society
World Glaucoma Week Raises Global Awareness of the Importance of Eye Health
-
Allon Adopts Shareholder Rights Plan
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 8, 2010) - Allon Therapeutics Inc. ("Allon" or the "Company") (TSX:NPC) announced today that its Board of Directors has approved in principle the adoption of a Shareholder Rights Plan Agreement (the "Rights Plan"). The Rights Plan is being adopted to ensure the fair treatment of all Allon shareholders in connection with any possible future take-over bids for the outstanding common shares of Allon. The Rights Plan will provide shareholders with adequate time to properly evaluate and assess a take-over bid without facing undue pressure or coercion. The Rights Plan is similar to the rights plans adopted by other Canadian companies.
-
MDRNA, Inc. Announces Upcoming Investor Conference Presentations
BOTHELL, WA--(Marketwire - March 8, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that J. Michael French, MDRNA's President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at the following upcoming conferences:
-
CTD Holdings, Inc. Reorganizes Structure to Better Emphasize Branded Products, Trappsol(R) and Aquaplex(R)
HIGH SPRINGS, FL--(Marketwire - March 8, 2010) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) today announced its plans to move the company's Aquaplex® product line out of the CTD, Inc. division and into NanoSonic Products, Inc. (NSP). The decision was made as a result of a successful orphan drug application filing made to the U.S. Food and Drug Administration for Trappsol® CycloT (hydroxypropyl beta cyclodextrin) in the treatment of Niemann Pick Type C disease.
-
Entest BioMedical Announces Creation of Proprietary Adult Stem Cell Lines
To Serve as Platform for Screening of Regenerative Photoceuticals
-
Stellar Pharmaceuticals Allowed Uracyst(R) Patent in China
LONDON, ONTARIO--(Marketwire - March 8, 2010) - Stellar Pharmaceuticals Inc. (OTCBB:SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it has been informed by the Chinese Patent Office that a patent has been allowed for one of its lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS").
-
Auxilium Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
MALVERN, PA--(Marketwire - March 8, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL),
a specialty biopharmaceutical company, today announced that XIAFLEXT
(collagenase clostridium histolyticum), a novel,
first-in-class,
orphan-designated, biologic, is now available by prescription in the United
States for the treatment of adult Dupuytren's contracture patients with a
palpable cord.
-
Cypress Bioscience, Inc. to Present at Cowen and Company 30th Annual Health Care Conference
SAN DIEGO, CA--(Marketwire - March 8, 2010) - Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Cowen and Company 30th Annual Health Care Conference on March 10, 2010.
-
Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy
GLOSTRUP, DENMARK--(Marketwire - March 8, 2010) -
-
Pharma Market Research Managers Reevaluate Vendor Relationships
Business Intelligence Firm Cutting Edge Information Investigates Vendor Management
-
NASDAQ Puts BASi on Notice
WEST LAFAYETTE, IN--(Marketwire - March 5, 2010) - Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today that it received notification from the NASDAQ Listing Qualification Department on March 4, 2010 that it has failed to maintain at least a $1 minimum bid price for its common shares (the "Minimum Bid Requirement"), which is required for continued listing of the Company's common shares on the NASDAQ Capital Market.
-
RB Milestone fait le suivi de ProMetic
MONTREAL, QUEBEC--(Marketwire - 5 mars 2010) - ProMetic Sciences de la Vie inc. (TSX:PLI) (« ProMetic ») à le plaisir d'annoncer que RB Milestone Group, LLC (« RB Milestone ») fait maintenant le suivi de ProMetic et a produit un rapport de recherche sur la société.
-
RB Milestone Initiates Coverage of ProMetic
MONTREAL, QUEBEC--(Marketwire - March 5, 2010) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") is pleased to report that RB Milestone Group, LLC ("RB Milestone"), initiated coverage of ProMetic with a research report about the company.
-
RECORDATI : 2009 ACCOUNTS APPROVED BY THE BOARD. NET INCOME EUR 110.6 MILLION. DIVIDEND PER SHARE EUR 0.275 (+ 10%).
MILAN--(Marketwire - March 5, 2010) -
-
Medtech VCs Will Divulge Trends in European Dealmaking and Investing at Elsevier's 'IN3 Europe' Investor Conference in Paris, April 29-30, 2010
Strategic Partnership and Investment Meeting Precedes 'Medical Device Investor Day' at Same Venue on April 28th
-
Allon Reports 2009 Audited Operating Results and Updates 2010 Plans
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 5, 2010) - Allon Therapeutics Inc. (TSX:NPC) today announced its audited operating results for 2009 and updated clinical development plans for 2010.
-
Chembio Reports 2009 Results
Conference Call Scheduled for Friday, March 5, 2010, at 10:30 a.m. Eastern Time
-
Paradigm Medical Announces
SALT LAKE CITY, UT--(Marketwire - March 5, 2010) - Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that it has been notified by its Italian partner, Costruzione Strumenti Oftalmici (CSO), that all necessary documents have been completed and submitted to the United States Food and Drug Administration (FDA) for the RetimaxT, also known as the Paramax. Paradigm is the exclusive representative for this significant new product in the U.S. market. "This new innovative device offers the earliest detection of glaucoma currently available and will be an excellent addition to Paradigm's glaucoma diagnostic products," said Stephen Davis, Paradigm's President and Chief Executive Officer.
-
MIT Changes Its Name to Micro Identification Technologies
SAN CLEMENTE, CA--(Marketwire - March 5, 2010) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announced that it has changed its company name to Micro Identification Technologies to better reflect the extensive capabilities of its ID technology software. The company currently produces the MIT 1000 Rapid Microbial Identification (ID) System that can identify bacteria in less than five minutes with a laser that uses the principles of light scattering and with proprietary PC-based software algorithms to test bacteria samples at less than $0.10 per test.
-
Afexa Life Sciences Inc. Announces Change in Year-End
EDMONTON, ALBERTA--(Marketwire - March 5, 2010) - Afexa Life Sciences Inc. (TSX:FXA) (the "Company") announced today that it has changed its financial year-end from September 30 to March 31 to better synchronize its financial reporting and business planning with its natural business cycle and those of its key customers and suppliers. In future years the change in year-end will ease some of the administrative burden currently associated with the Company's September 30 fiscal year-end period.
-
Cannasat Therapeutics Reports Results for the Year Ended December 31, 2009
TORONTO, ONTARIO--(Marketwire - March 5, 2010) - Cannasat Therapeutics Inc. (TSX VENTURE:CTH), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the year ended December 31, 2009. Unless specified otherwise, all amounts are in Canadian dollars.
-
Ventana-Status of Negotiations
NEW YORK, NEW YORK--(Marketwire - March 4, 2010) - Ventana Biotech Inc. ("Ventana") (PINK SHEETS:VNTA), a biotechnology company developing an appetite-suppressing and stress reducing chewing gum, announces today that it has terminated negotiations regarding the potential sale of its intellectual property to a third party.
-
King Pharmaceuticals to Present at Cowen & Co. Healthcare Conference
BRISTOL, TN--(Marketwire - March 4, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) today announced plans to provide a live webcast of its presentation scheduled for Wednesday, March 10, 2010, at 10:15 a.m. ET, at the Cowen & Co. 30th Annual Healthcare Conference at the Marriott Copley Place Hotel in Boston, Massachusetts. The presentation may include a discussion of the Company's marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business.
-
The Discoverer of PSA Pleased to Learn American Cancer Society Finally Agrees With His Long Standing Position
The PSA Test Could Not and Cannot Do What It Has Been Purported to Do for Screening for Prostate Cancer, According to Dr. Richard J. Ablin (Robert Benjamin Ablin Foundation for Cancer Research)
-
Selective Automation a Must for Clinical Labs to Remain Competitive
NEW YORK, NY--(Marketwire - March 4, 2010) - While clinical laboratories are vital to the diagnostic industry, they are facing multiple challenges that will require increased automation in order for them to remain competitive. But they must not go about the process of implementation haphazardly without a proper work flow analysis, or they may see no real improvements, according to healthcare market research publisher Kalorama Information's "Lab Automation Markets, 2nd Edition (Systems, Key Companies, Forecasts and Trends)." The report forecasts $5.35 billion in sales of clinical lab automation hardware and software in 2010, with growth through 2014 estimated at about 7%.
-
Amarillo Biosciences and Intas Pharmaceuticals Sign License and Supply Agreement to Use Oral Interferon to Treat Influenza in India and Nepal
Intas Pharmaceutical to Launch Phase 3 Clinical Trial in India to Test Amarillo Biosciences' Oral Interferon Against Influenza
-
Biotech Distributor BDI Pharma to Continue Accepting Flu Pre Books as New H1N1 Recommendation for Seasonal Vaccine Emerges
COLUMBIA, SC--(Marketwire - March 4, 2010) - BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, will continue accepting pre book orders for the 2010 - 2011 flu season, as recent recommendations provided by the FDA's Vaccines and Related Biological Products Advisory Committee suggest that manufacturers include the H1N1 strain in the upcoming seasonal flu vaccine. Due to these recommendations, BDI anticipates an uptake in pre book orders.
-
KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion
DEERFIELD, IL--(Marketwire - March 4, 2010) - Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEXT (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANTT (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
-
Inotek Pharmaceuticals to Present at the Cowen 30th Annual Health Care Conference on Thursday, March 11
LEXINGTON, MA--(Marketwire - March 4, 2010) - Inotek Pharmaceuticals Corp., a clinical-stage drug development company advancing innovative drug candidates to address significant eye disease, with a major focus on glaucoma, today announced that Paul G. Howes, President and CEO, will present a corporate overview at the Cowen and Company 30th Annual Health Care Conference on Thursday March 11, 2010 at 9:30 a.m. Eastern Time. The conference will be held at the Boston Marriott Copley Place Hotel, Boston, MA.
-
Duane Reade Opens New Chelsea Store Location Featuring Expanded Fresh Food and Grocery Offerings
New 24 Hour Location Opens on 16th Street and 8th Avenue
-
IBEX : Avis de l'Assemblée annuelle des actionnaires
MONTRÉAL, QUÉBEC--(Marketwire - 4 mars 2010) - Technologies IBEX Inc. (TSX CROISSANCE:IBT)
rappelle à ses actionnaires que l'Assemblée annuelle des actionnaires se
tiendra à 8 h 30 le 16 mars 2010, à l'Hôtel Ruby Foos, au 7655,
boulevard Décarie à Montréal.
-
IBEX Notice of Annual Meeting of Shareholders
MONTREAL, QUEBEC--(Marketwire - March 4, 2010) - IBEX Technologies Inc. (TSX VENTURE:IBT), reminds shareholders that the Annual Meeting of Shareholders will be held at 8:30 AM on March 16, 2010 at the Hotel Ruby Foos, 7655 Decarie Boulevard, Montreal.
-
Lorus Therapeutics Announces Resignation of Director
TORONTO, ONTARIO--(Marketwire - March 4, 2010) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today reported that Mr. Georg Ludwig, HighTech Beteiligungen GmbH & Co. KG's ("HighTech") representative on Lorus' board of directors (the "Board") has resigned effective March 3, 2010.
-
Hu-Friedy Sponsors Dental Hygienists at Chicago Midwinter Dental Society Meeting
Company Honors Winners of Essay Contest for Their Contributions to Better Dentistry
-
Paragon Pharmacies Limited Names New CEO
KELOWNA, BRITISH COLUMBIA--(Marketwire - March 4, 2010) - Martin Weinberg, Chairman of the Board of Directors of Paragon Pharmacies Limited (TSX VENTURE:PGN) ("Paragon" or "the Company") announced today the appointment of Robert (Gordon) Gooding, CA, as the Chief Executive Officer for the Company.
-
Functional Technologies Retains Brisco Capital to Provide Investor Relations Services
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 4, 2010) - Functional Technologies Corp. (TSX VENTURE:FEB) is pleased to announce that it has retained the services of Brisco Capital Partners Corp., of Calgary, Alberta to provide investor relations services. Brisco will work with Functional Technologies to initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the company and its developments.
-
Cleveland BioLabs Announces Annual Meeting
BUFFALO, NY--(Marketwire - March 4, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2010 annual stockholders meeting on June 8, 2010 in Buffalo, NY for stockholders of record as of April 9, 2010. The Company will distribute proxy materials to all eligible stockholders.
-
OmniComm Introduces TrialOne(TM) - an Integrated Suite of Web Based Solutions for Phase I Clinic Automation and Management
FORT LAUDERDALE, FL--(Marketwire - March 4, 2010) - OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web-based solution designed to automate the Phase I Clinical Trial Process. TrialOne provides all necessary web-based tools used to recruit study volunteers, schedule screening appointments, collect screening data, directly capture real-time data, track sample transfers and address the unique requirements of early phase studies. Within each study, real-time electronic data is captured and validated directly at the subject's bedside or at a subject queuing station. Enhanced workflow technology automates sample processing throughout the lab. TrialOne supports a myriad of directly attached biomedical monitoring devices such as the GE Healthcare DINAMAP® family of vital signs monitors and various ECG devi
-
Symbollon Hits Its First Major Milestone
Symbollon Initiates Sales of iogen Through Web Site buyiogen.com
-
EnWave Completes Successful powderREV(R) Technology Development Milestone in Collaboration with Danisco AS
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 4, 2010) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that the Company's latest prototype Radiant Energy Vacuum ("REV") dehydration technology, powderREV®, has been successfully used to dry kilogram quantities of probiotic cultures provided by collaboration partner, Danisco AS, with excellent viability and low final moisture levels. This successful trial represents the completion of another important milestone in the development and commercialization of the Company's powderREV® technology which is being designed as a high-speed, lower-energy, continuous alternative to freeze drying, the current industry method for dehydrating liquids containing sensitive materials. Dried food cultures benefit manufacturers significantly in permitting a wider range of storage co
-
ImmuneRegen BioSciences Submits Homspera(R) for FDA Orphan Drug Product Designation for the Treatment of Idiopathic Pulmonary Fibrosis
Company to Continue Developmental Work on Idiopathic Pulmonary Fibrosis in Conjunction With the University of Rochester
-
Good Health Media Now Fastest-Growing Health Network
Audience Grew 93% in 2009 as Niche Health Sites Attracted Greater Audience; Advertising Rose 56% in Q409, Fueled by Deals With Wal-Mart Pharmacy, Shire, J&J and Merck
-
Auxilium Pharmaceuticals to Present at the Cowen and Co. 30th Annual Health Care Conference
MALVERN, PA--(Marketwire - March 4, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
today announced that executive management will participate in the Cowen and
Co. 30th Annual Health Care Conference to be held March 8 - 11, 2010 at The
Boston Marriott Copley Place. Mr. Jim Fickenscher, Chief Financial
Officer, is scheduled to present an overview of the Company and its product
pipeline at 10:20a.m. ET on Thursday, March 11, 2010.
-
Eurand Reports Recent Developments and Fourth Quarter and Full-Year 2009 Financial Results
AMSTERDAM, THE NETHERLANDS--(Marketwire - March 4, 2010) - Eurand N.V. (NASDAQ: EURX)
-
IntelGenx and Cannasat Announce Letter of Intent for Relivar License
SAINT LAURENT, QUEBEC AND TORONTO, ONTARIO--(Marketwire - March 4, 2010) - IntelGenx Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) and Cannasat Therapeutics Inc. (TSX VENTURE:CTH) announced today that they have entered into a Letter of Intent ("LOI"). Under the terms of the LOI, IntelGenx would acquire a fifty percent ownership stake from Cannasat and an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol, utilizing IntelGenx's proprietary mucoadhesive AdVersa technology, for the treatment of various diseases including neuropathic pain.
-
Retinal Innovation Symposium and Dining in the Dark March Event in Southern California Already Attracting Hundreds of Attendees
Retinal Degenerative Research Experts Will Gather With Drug and Device Developers, to Speed Development of Important New Modalities; Event Co-Chaired by Versant Ventures Managing Director, William J. Link, Ph.D., and Internationally Recognized Retinal UCI Specialist Dr. Baruch Kuppermann
-
Urologist Dr. J. Francois Eid, MD Warns Against the Dangers of Online Herbal Remedies for Erectile Dysfunction (ED)
NEW YORK, NY--(Marketwire - March 3, 2010) - News reports coming out of the UK and Australia show evidence of prescription ingredients in many "natural" herb remedies sold on the Internet to treat erectile dysfunction (ED). These popular online supplements, which claim to consist only of homeopathic ingredients, are often improperly labeled and may actually contain dangerous ingredients. Dr. J. Francois Eid, director and founder of Advanced Urological Care in New York City, is concerned about this practice, especially since, in his experience, men with erectile dysfunction choose to suffer in silence rather than seek medical help for their condition.
-
AOAC concede aprobación de prueba FoodChek(TM)-E. coli O157 para muestra de 375g
CALGARY, ALBERTA--(Marketwire - March 3, 2010) -
FoodChek Systems Inc. ("FoodChek") (anteriormente Vacci-Test Corporation) se complace en anunciar que el AOAC Research Institute (Instituto de Investigación de la Asociación de Químicos Analíticos Oficiales), el organismo de aprobación para todas las pruebas de seguridad de alimentos de Estados Unidos, aprobó una modificación a su prueba existente FoodChek(TM)-E. coli O157 de una muestra de 25g al tamaño de muestra estándar en la industria de 375g para la detección de E. coli O157 en la carne molida cruda. Esta extensión de aprobación de la AOAC también incluye los tamaños de muestras de compuestos de 65g y 325g.
-
Dr. David B. Samadi, MD Mount Sinai's Robotic Prostatectomy Expert, Shares Core Facts About Prostate Cancer
NEW YORK, NY--(Marketwire - March 3, 2010) - With more and more high profile celebrities being diagnosed with the "silent killer" known as prostate cancer (most recently the actor Louis Gossett Jr.), Dr. David B. Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, believes this is a good time to advise the public on the facts of prostate cancer.
-
Paladin et SpePharm annoncent une nouvelle relation d'affaires et un nouveau financement stratégiques
MONTREAL, CANADA--(Marketwire - 3 mars 2010) - Laboratoires Paladin Inc. (TSX:PLB), chef de file de l'industrie pharmaceutique spécialisée au Canada, a annoncé aujourd'hui son investissement stratégique dans la société SpePharm Holding B.V. SpePharm est une société pharmaceutique spécialisée qui connaît une croissance rapide et qui concentre ses efforts sur l'acquisition, l'obtention de droits de distribution sous licence et la commercialisation de médicaments spécialisés à valeur médicale élevée partout en Europe.
-
Paladin and SpePharm Announce New Strategic Relationship and Financing
MONTREAL, CANADA--(Marketwire - March 3, 2010) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced that it has made a strategic investment in SpePharm Holding B.V. SpePharm is a rapidly-growing, specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines throughout Europe.
U
-
Acceleware Announces Debt Settlement
CALGARY, ALBERTA--(Marketwire - March 3, 2010) - Acceleware Corp. (TSX VENTURE:AXE) (the "Company") a leading developer of high performance computing applications, is pleased to announce that on March 3, 2010 it settled outstanding indebtedness of $114,825.66 through the issuance of common shares of the Company ("Common Shares") at deemed prices of $0.05 per Common Share (the "Debt Settlement"), subject to TSX Venture Exchange final approval. The outstanding debt is comprised of employee wages and consulting fees. As part of the restructuring that occurred in 2008, certain employees voluntarily agreed to defer a portion of their salary and have now agreed to convert such debt into common shares. A total of 2,296,513 Common Shares were issued under the Debt Settlement. The Common Shares are subject to a four month hold period that expires on July 4, 2010.
-
Watson to Present at Cowen and Company 30th Annual Healthcare Conference
MORRISTOWN, NJ--(Marketwire - March 3, 2010) - Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010 at 11:05 am Eastern Standard Time at the Boston Marriott Copley Place.
-
AgraQuest Inc. Strengthens Financial Standing Ahead of Planned IPO
DAVIS, CA--(Marketwire - March 3, 2010) - AgraQuest Inc. today announced that it has significantly strengthened its financial standing by closing a transaction resulting in the conversion by Loudwater Trust Limited of its note with an original face value of $10 million, plus certain accrued interest, into AgraQuest preferred stock. Separately, AgraQuest announced that it has obtained a line of credit from Silicon Valley Bank to support working capital growth.
-
AccuDial Pharmaceutical Closes $4 Million Funding
PALM BEACH GARDENS, FL--(Marketwire - March 3, 2010) - AccuDial Pharmaceutical, Inc. announced today that their initial financing, a private placement for four million shares at $1 per share, has been successfully closed. This funding round was accomplished entirely by AccuDial's management team and board of directors without any institutional involvement.
-
The Coalition to Prevent Deep-Vein Thrombosis Launches the DVT Awareness in Motion National Education Program
Program Designed to Raise Awareness for DVT and Ways to Keep Your Body Active Everywhere
-
OnePoint Patient Care Launches Advanced Online Tool That Helps Hospices Improve Patient Care and Better Manage Drug Costs
OnePointRx Provides Suite of Reports Customized to Meet the Unique Needs of Hospices
-
AOAC aprova teste FoodChek(TM)-E. coli O157 para amostras de 375 g
CALGARY, ALBERTA--(Marketwire - March 3, 2010) -
A FoodChek Systems Inc. ("FoodChek") (ex-Vacci-Test Corporation) tem o prazer de anunciar que o AOAC Research Institute, a entidade de aprovação para todos os testes de segurança de alimentos nos EUA, aprovou uma modificação para o teste FoodChek(TM)-E. coli O157 para uma amostra de 25 g para o tamanho padrão do setor de 375 g para a detecção de E. coli O157 na carne moída crua. Esta extensão da aprovação do AOAC também inclui os tamanhos de amostras compostos de 65 g e de 325 g.
-
CareerBoard Launches Job Board to Connect San Francisco Job Seekers With San Francisco Employers
-
CareerBoard Launches Job Board to Connect Seattle Job Seekers With Seattle Employers
-
Parks Associates Predicts Expanded Adoption for Personal Health Records Due to $19 Billion Government Incentive
Government EMR Incentive Raises PHR Visibility and Promotes Usage
|